Marked elevation of alkaline phosphatase in an infant treated with levetiracetam: A case report.

Kim Dao, Emmannuella Bonègre, Hassib Chehade, Sébastien Lebon

Abstract readCase Reports

In one paragraph

Article in Epilepsy & behavior reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kim DaoService of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

Emmannuella BonègreUnit of Paediatric Neurology and Neurorehabilitation, Department Mother-Woman-Child, Lausanne University Hospital, and University of Lausanne, Lausanne, Switzerland.

Hassib ChehadeDivision of Pediatric Nephrology, Department Mother-Woman-Child, Lausanne University Hospital, and University of Lausanne, Lausanne, Switzerland.

Sébastien LebonUnit of Paediatric Neurology and Neurorehabilitation, Department Mother-Woman-Child, Lausanne University Hospital, and University of Lausanne, Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Levetiracetam (LEV) is widely used in the treatment of pediatric epilepsy and is typically well tolerated. We hereby present a case involving an infant who exhibited a notable and isolated elevation of alkaline phosphatase (ALP) during a treatment of LEV, with subsequent normalization following drug cessation. Liver function tests and bone turnover markers remained within normal limits, and the patient was asymptomatic. ALP levels returned to normal within four weeks of discontinuing LEV. LEV may cause significant, reversible ALP elevation in children, most likely due to bone origin. Although rare, this potential adverse effect should be considered, particularly during long-term therapy.

Indexed as

Adverse drug eventCase reportEpilepsyLevetiracetamPediatric

Identifiers

PMID42775129

DOI10.1016/j.ebr.2026.100896

PMCPMC13595205

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.